1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Thymus Carcinoma Global Clinical Trials Review, H1, 2015

Thymus Carcinoma Global Clinical Trials Review, H1, 2015

  • February 2015
  • -
  • Global Data
  • -
  • 63 pages

Thymus Carcinoma Global Clinical Trials Review, H1, 2015

Summary

GlobalData's clinical trial report, “Thymus Carcinoma Global Clinical Trials Review, H1, 2015" provides data on the Thymus Carcinoma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Thymus Carcinoma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Thymus Carcinoma. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

Table Of Contents

Thymus Carcinoma Global Clinical Trials Review, H1, 2015
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Introduction 5
Thymus Carcinoma 5
Report Guidance 5
Clinical Trials by Region 6
Clinical Trials and Average Enrollment by Country 7
Top Countries Contributing to Clinical Trials in Asia-Pacific 9
Top Countries Contributing to Clinical Trials in Europe 10
Top Countries Contributing to Clinical Trials in North America 11
Clinical Trials by G7 Countries: Proportion of Thymus Carcinoma to Oncology Clinical Trials 12
Clinical Trials by Phase in G7 Countries 13
Clinical Trials in G7 Countries by Trial Status 14
Clinical Trials by E7 Countries: Proportion of Thymus Carcinoma to Oncology Clinical Trials 15
Clinical Trials by Phase 16
In Progress Trials by Phase 17
Clinical Trials by Trial Status 18
Clinical Trials by End Point Status 19
Unaccomplished Trials of Thymus Carcinoma 20
Subjects Recruited Over a Period of Time 21
Clinical Trials by Sponsor Type 22
Prominent Sponsors 23
Prominent Drugs 24
Clinical Trial Profiles 25
Clinical Trial Overview of Top Companies 25
Nerviano Medical Sciences S.r.l. 25
Clinical Trial Overview of Nerviano Medical Sciences S.r.l. 25
Clinical Trial Overview of Top Institutes / Government 26
National Cancer Institute 26
Clinical Trial Overview of National Cancer Institute 26
Duke University 27
Clinical Trial Overview of Duke University 27
Shanghai Chest Hospital 28
Clinical Trial Overview of Shanghai Chest Hospital 28
Korean Cancer Study Group 29
Clinical Trial Overview of Korean Cancer Study Group 29
Istituto Clinico Humanitas 30
Clinical Trial Overview of Istituto Clinico Humanitas 30
Indiana University 31
Clinical Trial Overview of Indiana University 31
Memorial Sloan Kettering Cancer Center 32
Clinical Trial Overview of Memorial Sloan Kettering Cancer Center 32
Georgetown University 33
Clinical Trial Overview of Georgetown University 33
Indiana University School of Medicine 34
Clinical Trial Overview of Indiana University School of Medicine 34
Valley Health System 35
Clinical Trial Overview of Valley Health System 35
Five Key Clinical Profiles 36
Appendix 61
Abbreviations 61
Definitions 61
Research Methodology 62
Secondary Research 62
About GlobalData 63
Contact Us 63
Disclaimer 63
Source 63

List of Tables
Thymus Carcinoma Therapeutics, Global, Clinical Trials by Region, 2015* 6
Thymus Carcinoma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015* 7
Thymus Carcinoma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015* 8
Thymus Carcinoma Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2015* 9
Thymus Carcinoma Therapeutics Clinical Trials, Europe, Top Countries, 2015* 10
Thymus Carcinoma Therapeutics Clinical Trials, North America, Top Countries, 2015* 11
Proportion of Thymus Carcinoma to Oncology Clinical Trials, G7 Countries (%), 2015* 12
Thymus Carcinoma Therapeutics, G7 Countries, Clinical Trials by Phase, 2015* 13
Thymus Carcinoma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015* 14
Proportion of Thymus Carcinoma to Oncology Clinical Trials, E7 Countries (%), 2015* 15
Thymus Carcinoma Therapeutics, Global, Clinical Trials by Phase, 2015* 16
Thymus Carcinoma Therapeutics, Global, Clinical Trials In Progress by Phase 2015* 17
Thymus Carcinoma Therapeutics, Global, Clinical Trials by Trial Status, 2015* 18
Thymus Carcinoma Therapeutics Clinical Trials, Global, by End Point Status, 2015* 19
Thymus Carcinoma Therapeutics, Global, Terminated Clinical Trials, 2015* 20
Thymus Carcinoma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2010-2014 21
Thymus Carcinoma Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2015* 22
Thymus Carcinoma Therapeutics Clinical Trials, Global, Key Sponsors, 2015* 23
Thymus Carcinoma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015* 24
Thymus Carcinoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Nerviano Medical Sciences S.r.l., 2015* 25
Thymus Carcinoma Therapeutics Clinical Trials Market, Global, Clinical Trials by National Cancer Institute, 2015* 26
Thymus Carcinoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Duke University, 2015* 27
Thymus Carcinoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Shanghai Chest Hospital, 2015* 28
Thymus Carcinoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Korean Cancer Study Group, 2015* 29
Thymus Carcinoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Istituto Clinico Humanitas, 2015* 30
Thymus Carcinoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Indiana University, 2015* 31
Thymus Carcinoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Memorial Sloan Kettering Cancer Center, 2015* 32
Thymus Carcinoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Georgetown University, 2015* 33
Thymus Carcinoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Indiana University School of Medicine, 2015* 34
Thymus Carcinoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Valley Health System, 2015* 35

List of Figures
Thymus Carcinoma Therapeutics, Global, Clinical Trials by Region (%), 2015* 6
Thymus Carcinoma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015* 7
Thymus Carcinoma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015* 8
Thymus Carcinoma Therapeutics Clinical Trials, Asia-Pacific, Top Countries (%), 2015* 9
Thymus Carcinoma Therapeutics Clinical Trials, Europe, Top Countries (%), 2015* 10
Thymus Carcinoma Therapeutics Clinical Trials, North America, Top Countries (%), 2015* 11
Proportion of Thymus Carcinoma to Oncology Clinical Trials, G7 Countries (%), 2015* 12
Thymus Carcinoma Therapeutics, G7 Countries, Clinical Trials by Phase, 2015* 13
Thymus Carcinoma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015* 14
Proportion of Thymus Carcinoma to Oncology Clinical Trials, E7 Countries (%), 2015* 15
Thymus Carcinoma Therapeutics, Global, Clinical Trials by Phase (%), 2015* 16
Thymus Carcinoma Therapeutics, Global, Clinical Trials In Progress by Phase, 2015* 17
Thymus Carcinoma Therapeutics, Global, Clinical Trials by Trial Status, 2015* 18
Thymus Carcinoma Therapeutics Clinical Trials, Global, by End Point Status, 2015* 19
Thymus Carcinoma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2010-2014 21
Thymus Carcinoma Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2015* 22
Thymus Carcinoma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015* 24
GlobalData Methodology 62

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers
Non-Small Cell Lung Cancer (NSCLC) - 5EU Drug Forecast and Market Analysis to 2025

Non-Small Cell Lung Cancer (NSCLC) - 5EU Drug Forecast and Market Analysis to 2025

  • $ 6995
  • Industry report
  • November 2016
  • by Global Data

Non-Small Cell Lung Cancer (NSCLC) - 5EU Drug Forecast and Market Analysis to 2025 Summary Lung cancer is currently is the most common cause of death from cancer worldwide. Of total lung cancer incident ...

Epiomic Epidemiology Series: Cervical Cancer Forecast in 22 Major Markets 2016 - 2026

Epiomic Epidemiology Series: Cervical Cancer Forecast in 22 Major Markets 2016 - 2026

  • $ 5112
  • Industry report
  • October 2016
  • by Black Swan Analysis Ltd132

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Cervical Cancer in 22 Major Markets Cervical cancer (ICD-10 code C53, cervix uteri) is a type of cancer that occurs in the cells of ...

Non-Small Cell Lung Cancer (NSCLC) - China Drug Forecast and Market Analysis to 2025

Non-Small Cell Lung Cancer (NSCLC) - China Drug Forecast and Market Analysis to 2025

  • $ 4995
  • Industry report
  • November 2016
  • by Global Data

Non-Small Cell Lung Cancer (NSCLC) - China Drug Forecast and Market Analysis to 2025 Summary Lung cancer is currently is the most common cause of death from cancer worldwide. Of total lung cancer incident ...


ref:plp2015

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.